Latest News

US company Novavax has reported positive results from the Australian-based phase one trial of its investigative COVID-19 vaccine.

A leading group of contract research organisations under the auspices of ARCS Australia are calling on the federal government to improve policies and processes around the national coordination of clinical trials in Australia.

Janssen has teamed up with Monash University for a research and development program to advance the development of inhaled oxytocin for the prevention of postpartum hemorrhage in developing countries.

Australian company Adherium (ASX: ADR) has announced the appointment of Geoff Feakes as its chief technology officer (CTO).

AusBiotech congratulates the founders of medtech company SpeeDx for winning the coveted Clunies Ross Award for Innovation, in recognition of their dedication to fostering entrepreneurship and...

A Sydney-based cancer research group says it has achieved a 'world-first' by developing a technology that can analyse the proteins in cancer samples on a new scale. The results have been...

Register by Wednesday 5 August to save up to $200 on registration to AusBiotech + Invest 2020 –Australia’s biggest week in biotech that in October will feature the event you know and trust, with new opportunities for global delegates and speakers, and a new level of global insight and perspective.

Australian company Medlab Clinical (ASX.MDC) has reported positive data from the ongoing observational study of NanaBis that is in development as a non-opioid alternative for the treatment of cancer-induced bone pain. 

Australian company Hatchtech has announced commercialisation partner, Dr Reddy’s Laboratories, has secured US FDA approval of XEGLYZE (abametapir) Lotion 0.74% for the topical treatment of head lice in patients six months of age and older.

Antisense Therapeutics' [ASX:ANP) has announced it has submitted to the US FDA its application for orphan drug designation of ATL1102 for the treatment of Duchenne muscular dystrophy.

Australian company EpiAxis Therapeutics has announced new appointments to its board of directors as it works towards a partnership to progress the further development of its pipeline.

Perth-based SUDA Pharmaceuticals (ASX:SUD) has announced the TGA has approved its lead product ZolpiMist (zolpidem tartrate) for the treatment of short-term insomnia in adults.